JP2008520688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520688A5 JP2008520688A5 JP2007543221A JP2007543221A JP2008520688A5 JP 2008520688 A5 JP2008520688 A5 JP 2008520688A5 JP 2007543221 A JP2007543221 A JP 2007543221A JP 2007543221 A JP2007543221 A JP 2007543221A JP 2008520688 A5 JP2008520688 A5 JP 2008520688A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- ethoxy
- phenyl
- chromen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 229910003849 O-Si Inorganic materials 0.000 claims 9
- 229910003872 O—Si Inorganic materials 0.000 claims 9
- 102000015694 estrogen receptors Human genes 0.000 claims 8
- 108010038795 estrogen receptors Proteins 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 206010020718 hyperplasia Diseases 0.000 claims 5
- 210000000481 breast Anatomy 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 3
- PAUMCYOKUFGQRG-LJAQVGFWSA-N (2s)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3-(2-trimethylsilylethoxymethyl)-2h-chromen-7-ol Chemical compound C1=CC([C@H]2C(COCC[Si](C)(C)C)=C(C3=CC=C(O)C=C3O2)C)=CC=C1OCCN1CCCCC1 PAUMCYOKUFGQRG-LJAQVGFWSA-N 0.000 claims 2
- YKALNUZJEDZKJG-UHFFFAOYSA-N 6-[4-(2-piperidin-1-ylethoxy)phenyl]-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-ol Chemical compound O1C2=CC(O)=CC=C2C(CCCCC2)=C2C1C(C=C1)=CC=C1OCCN1CCCCC1 YKALNUZJEDZKJG-UHFFFAOYSA-N 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000033830 Hot Flashes Diseases 0.000 claims 2
- 206010060800 Hot flush Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 206010049088 Osteopenia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- -1 carboxy, amino Chemical group 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000583 progesterone congener Substances 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- PAUMCYOKUFGQRG-GDLZYMKVSA-N (2r)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3-(2-trimethylsilylethoxymethyl)-2h-chromen-7-ol Chemical compound C1=CC([C@@H]2C(COCC[Si](C)(C)C)=C(C3=CC=C(O)C=C3O2)C)=CC=C1OCCN1CCCCC1 PAUMCYOKUFGQRG-GDLZYMKVSA-N 0.000 claims 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- NMYMDQSWZHPVOQ-UHFFFAOYSA-N 2-[4-[2-(azepan-1-yl)ethoxy]phenyl]-4-(2-hydroxyethyl)-2h-chromen-7-ol Chemical compound O1C2=CC(O)=CC=C2C(CCO)=CC1C(C=C1)=CC=C1OCCN1CCCCCC1 NMYMDQSWZHPVOQ-UHFFFAOYSA-N 0.000 claims 1
- BCAHYKSCCYDNLZ-UHFFFAOYSA-N 3-(hydroxymethyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-7-ol Chemical compound O1C2=CC(O)=CC=C2C(C)=C(CO)C1C(C=C1)=CC=C1OCCN1CCCCC1 BCAHYKSCCYDNLZ-UHFFFAOYSA-N 0.000 claims 1
- FANGYSXRPPSHRV-UHFFFAOYSA-N 4-(2-hydroxyethyl)-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-7-ol Chemical compound O1C2=CC(O)=CC=C2C(CCO)=CC1C(C=C1)=CC=C1OCCN1CCCCC1 FANGYSXRPPSHRV-UHFFFAOYSA-N 0.000 claims 1
- SXENAAYLHGRIAZ-UHFFFAOYSA-N 4-cyclopentyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-7-ol Chemical compound O1C2=CC(O)=CC=C2C(C2CCCC2)=CC1C(C=C1)=CC=C1OCCN1CCCCC1 SXENAAYLHGRIAZ-UHFFFAOYSA-N 0.000 claims 1
- ZAOFBTDRLXTTRR-UHFFFAOYSA-N 4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-7-ol Chemical compound O1C2=CC(O)=CC=C2C(C)=CC1C(C=C1)=CC=C1OCCN1CCCCC1 ZAOFBTDRLXTTRR-UHFFFAOYSA-N 0.000 claims 1
- PAUMCYOKUFGQRG-UHFFFAOYSA-N 4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3-(2-trimethylsilylethoxymethyl)-2h-chromen-7-ol Chemical compound O1C2=CC(O)=CC=C2C(C)=C(COCC[Si](C)(C)C)C1C(C=C1)=CC=C1OCCN1CCCCC1 PAUMCYOKUFGQRG-UHFFFAOYSA-N 0.000 claims 1
- IFANTIOZECIHCH-UHFFFAOYSA-N 5-[4-(2-piperidin-1-ylethoxy)phenyl]-1,2,4,5-tetrahydropyrano[3,4-c]chromen-8-ol Chemical compound O1C2=CC(O)=CC=C2C(CCOC2)=C2C1C(C=C1)=CC=C1OCCN1CCCCC1 IFANTIOZECIHCH-UHFFFAOYSA-N 0.000 claims 1
- QYHKGMAAOCANDP-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]phenyl]-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-ol Chemical compound C1=CC(OCCN(C)C)=CC=C1C1C(CCCCC2)=C2C2=CC=C(O)C=C2O1 QYHKGMAAOCANDP-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- 238000011262 co‐therapy Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- RLJYJQLEYYYFCL-UHFFFAOYSA-N tert-butyl-dimethyl-[[5-[4-(2-piperidin-1-ylethoxy)phenyl]-1,2,4,5-tetrahydropyrano[3,4-c]chromen-8-yl]oxy]silane Chemical compound O1C2=CC(O[Si](C)(C)C(C)(C)C)=CC=C2C(CCOC2)=C2C1C(C=C1)=CC=C1OCCN1CCCCC1 RLJYJQLEYYYFCL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62898704P | 2004-11-18 | 2004-11-18 | |
| PCT/US2005/041648 WO2006055694A1 (en) | 2004-11-18 | 2005-11-17 | Novel 2h-chromene derivatives as selective estrogen receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520688A JP2008520688A (ja) | 2008-06-19 |
| JP2008520688A5 true JP2008520688A5 (cg-RX-API-DMAC7.html) | 2009-01-15 |
Family
ID=35883498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543221A Withdrawn JP2008520688A (ja) | 2004-11-18 | 2005-11-17 | 選択的エストロゲン受容体モジュレーターとしての新規な２ｈ−クロメン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060166933A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1812417B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008520688A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101103011A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE412643T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005307704A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2587669A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602005010735D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1812417T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2314747T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL1812417T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1812417E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1812417T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006055694A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016189011A1 (en) * | 2015-05-26 | 2016-12-01 | F. Hoffmann-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| US20200390755A1 (en) * | 2018-08-01 | 2020-12-17 | Shaanxi Micot Technology Co., Ltd. | Compound for treating nervous system diseases and use thereof |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE10013782A1 (de) * | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| IL161325A0 (en) * | 2001-11-19 | 2004-09-27 | Lilly Co Eli | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| US7329654B2 (en) * | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
-
2005
- 2005-11-17 AU AU2005307704A patent/AU2005307704A1/en not_active Abandoned
- 2005-11-17 CN CNA2005800468519A patent/CN101103011A/zh active Pending
- 2005-11-17 ES ES05824228T patent/ES2314747T3/es not_active Expired - Lifetime
- 2005-11-17 SI SI200530558T patent/SI1812417T1/sl unknown
- 2005-11-17 JP JP2007543221A patent/JP2008520688A/ja not_active Withdrawn
- 2005-11-17 PL PL05824228T patent/PL1812417T3/pl unknown
- 2005-11-17 DE DE602005010735T patent/DE602005010735D1/de not_active Expired - Fee Related
- 2005-11-17 US US11/281,074 patent/US20060166933A1/en not_active Abandoned
- 2005-11-17 WO PCT/US2005/041648 patent/WO2006055694A1/en not_active Ceased
- 2005-11-17 PT PT05824228T patent/PT1812417E/pt unknown
- 2005-11-17 CA CA002587669A patent/CA2587669A1/en not_active Abandoned
- 2005-11-17 DK DK05824228T patent/DK1812417T3/da active
- 2005-11-17 AT AT05824228T patent/ATE412643T1/de not_active IP Right Cessation
- 2005-11-17 EP EP05824228A patent/EP1812417B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6364028B2 (ja) | 選択的エストロゲン受容体ディグレーダーとしてのベンゾチオフェン誘導体およびその組成物 | |
| TWI568733B (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| AU2023201399A1 (en) | Modulators of the integrated stress pathway | |
| JP2020506951A5 (cg-RX-API-DMAC7.html) | ||
| JP2014528433A5 (cg-RX-API-DMAC7.html) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| KR20230121756A (ko) | Fgfr 억제제 및 이의 제조 및 사용 방법 | |
| HRP20100366T1 (hr) | Antagonisti receptora progesterona | |
| JP4582456B2 (ja) | ８−アザプロスタグランジン誘導体およびその医薬用途 | |
| JP7348665B2 (ja) | 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体 | |
| WO2009045503A1 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| TWI616445B (zh) | 新穎環丙苯并呋喃基吡啶并吡二酮類 | |
| JP2011517440A (ja) | 中枢神経系障害を処置するためのアザインドール化合物 | |
| JP2016531880A (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
| WO2005053707A1 (ja) | 馬尾神経組織血流増加剤 | |
| JP2008520688A5 (cg-RX-API-DMAC7.html) | ||
| JP2003516994A5 (cg-RX-API-DMAC7.html) | ||
| TW202327611A (zh) | 使用ｂｔｋ抑制劑和ｐ１３激酶抑制劑的組合治療癌症之方法 | |
| WO2025145091A1 (en) | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases | |
| JP2008509999A5 (cg-RX-API-DMAC7.html) | ||
| TW202024083A (zh) | 3,9-二氮雜螺[5.5]十一烷化合物 | |
| HK1231481B (zh) | 作为γ-分泌酶调节剂的色烯和1，1A，2，7B-四氢环丙烷并[C]色烯吡啶并吡嗪二酮 | |
| HK1242315B (zh) | 新颖环丙苯并呋喃基吡啶并吡嗪二酮类 | |
| HK1242315A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| OA18058A (en) | Chromene and 1,1 A,2,7B-tetrahydrocyclopropa[C]chromene pyridopyrazinediones as gamma-secretase modulators. |